GOALS & OBJECTIVES
Clinical and Economic Factors of Combination Therapy in Asthma
Slide Lecture
Activity Date: April 2002  — Activity Info: Volume2, (S2)
Goals & Objectives | Faculty | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired) | Order Copy of Activity

 

GOAL
To provide physicians and pharmacists with practical information for assessing the clinical and economic factors of dual-controller therapies for asthma management.

TARGET AUDIENCE
This activity is designed for pulmonologists, allergists, immunologists, primary care physicians, and pharmacists who manage and treat patients with asthma.

LEARNING OBJECTIVES
National Heart, Lung, and Blood Institute (NHLBI) guidelines for asthma management recommend that anti-inflammatory medications be the foundation of pharmacotherapy for persistent asthma in view of the importance of inflammation in asthma pathophysiology. For moderate or severe persistent asthma, dual-controller regimens (ie, combinations of two or more therapies with complementary mechanisms of action) are advised. The past decade has seen an explosion of research on dual-controller options for asthma therapy. This slide set discusses the sources of information that health care providers should consider in choosing among dual-controller regimens and reviews the newest data on the dual-controller options. Upon completion of this program, participants will be able to:

  • Consider the empirical sources of information health care providers should use in evaluating the relative value of pharmacotherapies;
  • Understand the strengths and weaknesses of randomized, controlled clinical trials versus observational studies;
  • Become familiar with data from randomized, controlled clinical trials of a new dual-controller regimen for asthma; and
  • Become familiar with clinical data from observational studies of a new dual-controller regimen for asthma.

ACCREDITATION STATEMENT
This activity has been planned and produced in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education. The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The Johns Hopkins School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this continuing medical education activity for a maximum of 1 hour in category 1 credit toward the American Medical Association Physicians' Recognition Award. Each physician should claim only those hours of credit that are actually spent on the educational activity. Credits are available until the expiration date of January 31, 2004.

This continuing education activity was produced under the supervision of Peter S. Creticos, MD, Associate Professor of Medicine, Johns Hopkins University School of Medicine, Clinical Director, Division of Allergy and Clinical Immunology; and Medical Director, Asthma and Allergy Diseases, Johns Hopkins Asthma & Allergy Center.

This program is approved for 1 hour of credit (0.1 CEUs) and is co-sponsored with the University of Tennessee College of Pharmacy, which is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. ACPE Program #064-999-02-211-H01.

This program is supported by an unrestricted educational grant from GlaxoSmithKline.

FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES

FACULTY MEMBER
Peter S. Creticos, MD, reports grant/research support from, serving as a consultant to, and is a member of the speakers' bureau for ALK, Allergenics, Aradigon, Aventis, AstraZeneca, Dynarax, GlaxoSmithKline, Janssen, McNeil, Merck, Pfizer, Pharmacia & Upjohn, Schering-Plough, and Stallergens.

Michael S. Blaiss, MD, reports receiving honoraria from, serving as a consultant to, and is a shareholder for GlaxoSmithKline, Merck, and Aventis.

Richard D. O'Connor, MD, reports serving as a consultant to Health Benchmarks Inc. and on the speakers' bureau for GlaxoSmithKline, Aventis, Pfizer, Shering, and Pharmacia, and is a shareholder for Elan, GlaxoSmithKline, and Forest.

Samy Suissa, PhD, reports receiving grant/research support from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, and Schering-Plough; and serving as a consultant to Organon.

PUBLISHER'S NOTE AND DISCLAIMER
The opinions expressed in this issue are those of the authors, presenters, and/or panelists and are not attributable to the publisher, editor, advisory board of Advanced Studies in Medicine, or The Johns Hopkins University School of Medicine or its Office of Continuing Medical Education. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this issue are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Advanced Studies in Medicine (ISSN-1530-3004) is published by Galen Publishing, LLC, an HMG Company. P.O. Box 340, Somerville, NJ 08876. (908) 253-9001. Web site: www.galenpublishing.com. Copyright ©2001 by Galen Publishing, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. Bulk postage paid at Somerville, NJ Post Office and at additional mailing offices. Advanced Studies in Medicine is a registered trademark of The Healthcare Media Group, LLC. Printed on acid-free paper. BPA Membership applied for December 2000.

     
Home | Contact Us | View Account | Need Help?